Ocular Therapeutix Inc [OCUL] stock prices are down -1.34% to $11.78 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OCUL shares have gain 3.24% over the last week, with a monthly amount drifted -7.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on September 15, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $21. On March 18, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $17 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $15 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Outperform. TD Cowen upgraded its rating to Buy for this stock on June 20, 2024, and upped its price target to $11.
The stock price of Ocular Therapeutix Inc [OCUL] has been fluctuating between $5.78 and $13.85 over the past year. Currently, Wall Street analysts expect the stock to reach $25.75 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $11.78 at the most recent close of the market. An investor can expect a potential return of 118.59% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
The Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 56.66M for trailing twelve months, representing a drop of -18.14%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -4.03%, Pretax Profit Margin comes in at -3.83%, and Net Profit Margin reading is -3.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.7 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Ocular Therapeutix Inc [NASDAQ:OCUL]’s Current Ratio is 10.09. Also, the Quick Ratio is 10.02, while the Cash Ratio stands at 9.11. Considering the valuation of this stock, the price to sales ratio is 44.06, the price to book ratio is 6.66.
Transactions by insiders
Recent insider trading involved Anderman Todd, Chief Legal Officer, that happened on Oct 08 ’25 when 11132.0 shares were sold. Officer, TODD ANDERMAN completed a deal on Oct 08 ’25 to buy 11132.0 shares. Meanwhile, Chief Development Officer Kaiser Peter sold 9653.0 shares on Oct 02 ’25.
